Takeda
NHS England Expediting Access to Takeda's Exkivity for Certain NSCLC Patients
The agency brokered a deal between NICE and Takeda, under which the sponsor will provide the drug on a budget-neutral basis while NICE completes its appraisal.
Takeda, Point32Health Deal Could Offer Roadmap for Risk-Sharing Reimbursement in Precision Oncology
Premium
The drugmaker and insurer's outcomes-based agreement offers rebates for ALK-positive NSCLC patients who discontinue Alunbrig after three months.
Calithera Biosciences Acquires Takeda Cancer Drugs in $45M Deal
The company will begin Phase II trials of sapanisertib in NSCLC and mivavotinib in diffuse large B-cell lymphoma in 2022.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines
The New York-based drugmaker will further develop the anti-UBR5 molecules for treatment-resistant TNBC and ovarian cancers